Home › Leucemia mieloide acuta › California › Orange
Studi clinici su Leucemia mieloide acuta a Orange, CA
13 studi su Leucemia mieloide acuta cercano partecipanti presso sedi a Orange e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
In reclutamentoFase 2
- UCI Health Chao Family Comprehensive Cancer Center, Orange
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
In reclutamentoFase 2
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
In reclutamentoFase 3
- Children's Hospital of Orange County, Orange
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
In reclutamentoFase 1
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
In reclutamentoFase 1/2
- Children's Hospital of Orange County, Orange
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
In reclutamentoFase 3
- Children's Hospital of Orange County Main Campus - Orange, Orange
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
In reclutamentoFase 3
- University of California, Irvine, Orange
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
In reclutamentoFase 1
- UC Irvine Health Chao Family Comprehensive Cancer Center, Orange
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
In reclutamentoFase 1
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
In reclutamentoFase 4
- UCI Irvine Health, Orange
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
In reclutamentoStudio osservazionale
- Children's Hospital of Orange County (CHOC), Orange
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
In reclutamentoFase 2/3
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
In reclutamentoFase 1
- UC Irvine Health Chao Family Comprehensive Cancer Center, Orange
Studi su Leucemia mieloide acuta in altre città
- Houston, TX85 studi
- New York City, NY51 studi
- Boston, MA44 studi
- Baldwin Park, CA40 studi
- Seattle, WA40 studi
- Columbus, OH35 studi
- Philadelphia, PA34 studi
- Durham, NC33 studi
- Atlanta, GA30 studi
- Tampa, FL29 studi
- Chicago, IL26 studi
- Portland, OR25 studi
Altri studi a Orange
- Cancro del polmone non a piccole cellule25 studi
- Cancro metastatico20 studi
- Cancro colorettale16 studi
- Cancro ovarico16 studi
- Cancro pancreatico15 studi
- Cancro al seno14 studi
- Cancro ai polmoni14 studi
- Cancro alla prostata14 studi
- Cancro al fegato (carcinoma epatocellulare)14 studi
- Melanoma14 studi
- Cancro (tutti i tipi)13 studi
- Cancro dello stomaco13 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.